 | | Vol. 9.27 – 22 July, 2020 |
| |
|
|
| The authors showed, using a mouse model of squamous cell carcinoma, that tumor-initiating cells played a crucial role in creating a niche microenvironment that was required for tumor progression and drug resistance.
[Science] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers showed that the combination treatment of anti-PD1 and cisplatin enriched BMI1+ CSCs in head and neck squamous cell carcinoma (HNSCC) while inhibiting HNSCC growth.
[Cell Stem Cell] |
|
|
|
| Scientists showed that LEFTY1, a secreted inhibitor of NODAL/SMAD2 signaling, was produced by mammary progenitor cells and, concomitantly, suppressed SMAD2 and SMAD5 signaling to promote long-term proliferation of normal and malignant mammary epithelial cells.
[Cell Stem Cell] |
|
|
|
| Investigators describe the immunoreceptor tyrosine-based inhibition motif-containing Fc gamma receptor IIb for being critical in leukemic stem cell resistance and showed that targeting FcγRIIb downstream signaling, by using a Food and Drug Administration-approved BTK inhibitor, provided a successful therapeutic approach.
[Leukemia] |
|
|
|
| Scientists found that the expression of STAP-1 was aberrantly upregulated in chronic myeloid leukemia (CML) stem cells in patients’ bone marrow.
[Oncogene] |
|
|
|
| Knockdown of nerve growth factor receptor (NGFR) markedly reduced the size and number of spheroid formation of melanoma cells, which could be rescued by ectopically expressed NGFR.
[Cell Death & Disease] |
|
|
|
| Investigators present a method for label-free detection of circulating tumor cells from patient blood samples, by taking advantage of data analysis of bright field microscopy images.
[Scientific Reports] |
|
|
|
| Scientists performed studies of viability, type of cell death, cancer stem cell percent and glycosphingolipid expression on CSC and non-CSC after treatment of MDA-MB-231 and MDA-MB-453 triple-negative breast cancer cells with a newly developed thienopyridine anticancer compound.
[Scientific Reports] |
|
|
|
|
| The authors summarize the latest advances in the understanding of PI3K/AKT/SOX2-driven stemness and its intertwined relations to p53-signaling in DNA damage response under conditions of pluripotency, reprogramming, and transformation.
[International Journal of Molecular Sciences] |
|
|
|
|
| Karolinska Development AB announces that its portfolio company Aprea Therapeutics has decided to expand the enrollment of patients in its Phase I clinical trial evaluating eprenetapopt in TP53 mutant acute myeloid leukemia.
[Karolinska Development AB] |
|
|
|
| Aprea Therapeutics, Inc. announced the expansion of patient enrollment in its Phase I clinical trial evaluating eprenetapopt in TP53 mutant AML.
[Aprea Therapeutics, Inc.] |
|
|
|
| A historic €1.8-trillion (US$2.1-trillion) budget deal reached by European Union (EU) leaders to fund its next seven years — and its recovery from the coronavirus pandemic — has left scientists and research advocates disappointed.
[Nature News] |
|
|
|
|
| August 27 – August 29
Virtual |
|
|
|
|
|
| | Cincinnati Children’s Hospital Medical Center – Cincinnati, Ohio, United States |
|
|
|
| | West Virginia University – Morgantown, West Virginia, United States |
|
|
|
| | Lund University – Lund, Sweden |
|
|
|
| | Massachusetts General Hospital – Charlestown, Massachusetts, United States |
|
|
|
| | Shanghai Jiao Tong University – Shanghai, China |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
